Children's Oncology Group

儿童肿瘤学组

• 批准号: 10889845
• 负责人: TODD A ALONZO
• 金额: $ 157.63万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-19 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10889845
• 关键词: 1 year old; Acceleration; Acute; Acute Myelocytic Leukemia; Adolescent; Australia; Brain Stem Glioma; Canada; Cancer Center; Cancer Patient; Caring; Cause of Death; Cell Therapy; Child; Child Support; Childhood; Childhood Leukemia; Clinical; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Collection; Communities; Complication; Country; Development; Diagnosis; Disease; Dose; Eligibility Determination; Enrollment; Ensure; Family; Foundations; Functional disorder; Generations; Goals; Hormonal; Immunotherapy; Infrastructure; Institution; Interdisciplinary Study; Knowledge; Laboratories; Late Effects; Lead; Malignant Childhood Neoplasm; Malignant Neoplasms; Methods; Mission; Molecular; Morbidity - disease rate; National Cancer Institute; National Clinical Trials Network; Neuroblastoma; New Zealand; Organ; Outcome; Patients; Pediatric Hospitals; Pediatric Oncology Group; Pharmaceutical Preparations; Population Heterogeneity; Population Research; Positioning Attribute; Productivity; Prognosis; Quality of life; Rare Diseases; Research; Research Personnel; Scientist; Second Primary Cancers; Site; Survival Rate; Survivors; Tissues; Translational Research; United States; Universities; Work; anticancer research; cancer diagnosis; cancer therapy; chemotherapy; childhood cancer survivor; clinical translation; design; experience; health related quality of life; high risk; improved; improved outcome; innovation; member; multidisciplinary; novel therapeutic intervention; operation; organizational structure; reproductive; small molecule; success; survivorship; translational study

PROJECT SUMMARY Since the introduction of chemotherapy for the treatment of childhood leukemia more than 60 years ago, the prognosis of childhood cancer has improved dramatically. The overall 5-year survival rate for childhood cancers, many of which were uniformly fatal in the pre-chemotherapy era, is now 84%. Progress for a number of childhood cancers, however, has been limited, with approximately 50% of children with acute myelogenous leukemia, 50% of children with high-risk neuroblastoma, and more than 90% of children with brainstem glioma, still succumbing to their disease. In the US, cancer remains the leading cause of death from disease in children greater than one year of age. Moreover, the late effects of cancer treatment, including permanent organ and tissue damage, hormonal and reproductive dysfunction and second cancers, are of special concern, with more than 40% of the 500,000 survivors of childhood cancer (estimated as of 2020) experiencing a significant health related quality of life complication from childhood cancer and its treatment. Thus, despite our advances, development of new therapeutic approaches must be a priority for childhood cancer basic, translational and clinical researchers. The Children’s Oncology Group (COG), the world’s largest organization devoted exclusively to childhood and adolescent cancer research, was founded 20 years ago. The COG’s multidisciplinary research team, comprised of more than 9,000 members, conducts research at more than 220 leading children’s hospitals, universities, and cancer centers. This proposal is for COG, as part of the National Cancer Institute’s (NCI) National Clinical Trials Network (NCTN), to continue its collaborative research work that supports the mission of improving the outcome for all children with cancer. The COG will design and conduct clinical-translational studies for children with cancer that builds on an increasing understanding of the molecular basis for pediatric malignancies and has the highest potential to improve the outcome. Using innovative clinical trial designs suitable for the study of rare diseases, we will study novel therapeutic approaches including but not limited to targeted small molecule drugs, immunotherapies and cellular therapies. The COG research portfolio importantly also includes clinical trials focused on improving the quality of life for children with cancer and childhood cancer survivors. As more than 90% of children diagnosed with cancer in the US are treated at COG member institutions, COG has the ability to offer a diverse population of children with cancer and their families the opportunity to participate in innovative research. This research effort includes allowing for collection and annotation of biospecimens from all children with cancer, providing the foundation for discovery and accelerating the most promising research efforts conducted in laboratories around the world. The proposal is for support of the COG Network Operations Center, scientists who develop and conduct research, and for member sites to participate through enrollment of eligible subjects.

项目摘要 自从60多年前引入化学疗法以治疗儿童白血病以来 儿童癌症的预后急剧改善。儿童癌症的总体5年生存率， 在化学前时代，其中许多人统一致命，现在为84％。童年的进步 但是，癌症受到限制，大约50％的急性髓性白血病儿童，50％ 患有高危神经母细胞瘤的儿童，超过90％的脑干神经胶质瘤儿童仍屈服 他们的疾病。在美国，癌症仍然是疾病死亡的主要原因超过一个 年龄。此外，癌症治疗的后期作用，包括永久器官和组织损伤， 骑马和生殖功能障碍和第二癌特别关注，超过40％ 500,000次儿童癌症冲浪者（估计截至2020年），具有重大健康相关质量的 儿童癌症及其治疗的生活并发症。那就是我们的进步，发展新的 治疗方法必须是儿童癌症基础，翻译和临床研究人员的优先事项。 儿童肿瘤学小组（COG），世界上最大的组织专门致力于童年和 青少年癌症研究成立于20年前。 COG的多学科研究团队完成了 在9,000多名成员中，在220多家领先的儿童医院，大学和 癌症中心。该建议是针对COG的，作为国家癌症研究所（NCI）国家临床试验的一部分 网络（NCTN），继续其协作研究工作，以支持改善结果的使命 对于所有患有癌症的儿童。 COG将针对癌症儿童设计和进行临床翻译研究。 这是基于对儿科恶能的分子基础的越来越多的理解，并且具有最高的 使用适合研究罕见疾病研究的创新临床试验设计， 我们将研究新颖的治疗方法，包括但不限于靶向小分子药物， 免疫疗法和细胞疗法。 COG研究组合还重要地包括临床试验 专注于改善癌症和儿童癌症生存儿童的生活质量。不仅仅是 90％的在美国诊断出患有癌症的儿童在COG成员机构接受治疗，COG具有能力 为癌症及其家人提供多样化的儿童，有机会参加创新 研究。这项研究工作包括允许收集和注释所有孩子 癌症为发现和加速最有前途的研究工作提供基础 在世界各地的实验室中进行。该建议是为了支持COG网络操作中心， 开发和进行研究的科学家，以及成员站点通过入学 合格的主题。